HUP0500557A2 - Tiazolszármazékok alkalmazása mitokondriumok védelmére szolgáló gyógyszer előállítására - Google Patents

Tiazolszármazékok alkalmazása mitokondriumok védelmére szolgáló gyógyszer előállítására

Info

Publication number
HUP0500557A2
HUP0500557A2 HU0500557A HUP0500557A HUP0500557A2 HU P0500557 A2 HUP0500557 A2 HU P0500557A2 HU 0500557 A HU0500557 A HU 0500557A HU P0500557 A HUP0500557 A HU P0500557A HU P0500557 A2 HUP0500557 A2 HU P0500557A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
hydrogen atom
hydroxyl
medicine
Prior art date
Application number
HU0500557A
Other languages
English (en)
Inventor
Michel Auguet
Pierre-Etienne Chabrier De Lassauniere
Jeremiah Harnett
Original Assignee
Societe de Conseils de Recherches et d'ApplicationScientifiques (S.C.R.A.S.) Á
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et d'ApplicationScientifiques (S.C.R.A.S.) Á filed Critical Societe de Conseils de Recherches et d'ApplicationScientifiques (S.C.R.A.S.) Á
Publication of HUP0500557A2 publication Critical patent/HUP0500557A2/hu
Publication of HUP0500557A3 publication Critical patent/HUP0500557A3/hu
Publication of HU229425B1 publication Critical patent/HU229425B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Cleaning By Liquid Or Steam (AREA)
  • Accessory Of Washing/Drying Machine, Commercial Washing/Drying Machine, Other Washing/Drying Machine (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány szerint az (I) általános képletű vegyületek, ahol Ajelentése (A1) általános képletű csoport, ahol R5 jelentésehidrogénatom vagy alkilcsoport, R6 jelentése hidrogénatom vagy alkil-,cikloalkil-, hidroxil- vagy alkoxicsoport, R7 jelentése hidrogénatomvagy alkil-, cikloalkil-, hidroxil- vagy alkoxicsoport és R8 jelentésehidrogénatom vagy alkil-, cikloalkil-, hidroxil- vagy alkoxicsoport,vagy A jelentése (A2) általános képletű csoport, ahol R9 és R10jelentése egymástól függetlenül hidrogénatom vagy hidroxil-, alkil-vagy alkoxicsoport, R11 jelentése hidrogénatom vagy alkilcsoport ésR12 jelentése hidrogénatom vagy hidroxil-, alkil- vagy alkoxicsoport;B jelentése hidrogénatom vagy alkilcsoport; n értéke 0-5 közötti egészszám; R1 és R2 jelentése egymástól függetlenül hidrogénatom vagyalkil- vagy cikloalkilcsoport; R3 és R4 jelentése egymástólfüggetlenül hidrogénatom vagy alkilcsoport, vagy R3 és R4 a kapcsolódónitrogénatommal együtt heterociklusos csoportot alkot, amely összesen1-2 heteroatomot és 5-7 tagot tartalmaz, ahol a heterociklusoscsoportból a hiányzó tagokat az alábbiak közül választják: -CHR13-, -NR14-, -O- és -S- csoport, ahol R13 jelentése hidrogénatom,hidroxilcsoport, alkil- vagy alkoxicsoport, és R14 jelentésehidrogénatom vagy alkilcsoport vagy -COR15, -COOR15 vagy -CONR16R17általános képletű csoport, ahol R15 jelentése alkilcsoport, R16 és R17jelentése egymástól függetlenül hidrogénatom vagy alkilcsoport;mitokondriumok védelmére szolgáló gyógyszer, különösen máj-cirróziskezelésére szolgáló gyógyszer előállítására használhatók.
HU0500557A 2001-07-26 2002-07-25 Use of thiazole derivatives for preparing a medicine for protecting mitochondria HU229425B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109979A FR2827772B1 (fr) 2001-07-26 2001-07-26 Utilisation de derives de thiazoles pour preparer un medicament destine a proteger les mitochondries
PCT/FR2002/002660 WO2003009843A1 (fr) 2001-07-26 2002-07-25 Utilisation de derives de thiazoles pour preparer un medicament destine a proteger les mithochondries

Publications (3)

Publication Number Publication Date
HUP0500557A2 true HUP0500557A2 (hu) 2005-09-28
HUP0500557A3 HUP0500557A3 (en) 2006-02-28
HU229425B1 HU229425B1 (en) 2013-12-30

Family

ID=8865922

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0500484A HU228783B1 (en) 2001-07-26 2000-07-13 Dry cleaning apparatus and method capable of utilizing a siloxane solvent
HU0500557A HU229425B1 (en) 2001-07-26 2002-07-25 Use of thiazole derivatives for preparing a medicine for protecting mitochondria

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0500484A HU228783B1 (en) 2001-07-26 2000-07-13 Dry cleaning apparatus and method capable of utilizing a siloxane solvent

Country Status (26)

Country Link
US (3) US7345066B2 (hu)
EP (1) EP1414447B1 (hu)
JP (1) JP4491229B2 (hu)
KR (1) KR20040030843A (hu)
CN (1) CN1533276B (hu)
AT (1) ATE333876T1 (hu)
AU (1) AU2002341008B8 (hu)
BR (1) BR0211423A (hu)
CA (1) CA2455635C (hu)
CY (1) CY1106212T1 (hu)
DE (1) DE60213424T2 (hu)
DK (1) DK1414447T3 (hu)
ES (1) ES2268099T3 (hu)
FR (1) FR2827772B1 (hu)
HK (1) HK1069326A1 (hu)
HU (2) HU228783B1 (hu)
IL (2) IL159548A0 (hu)
IS (1) IS2366B (hu)
MX (1) MXPA04000752A (hu)
NO (1) NO334797B1 (hu)
NZ (1) NZ530368A (hu)
PL (1) PL206706B1 (hu)
PT (1) PT1414447E (hu)
RU (1) RU2297832C2 (hu)
TW (1) TWI309568B (hu)
WO (1) WO2003009843A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7101917B2 (en) 2003-04-14 2006-09-05 Hoffmann-La Roche Inc. Mitochrondrial permeability transition pore affinity labels and modulators
US7915304B2 (en) 2006-10-24 2011-03-29 Congenia S.R.L. Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT
KR100970814B1 (ko) * 2009-06-01 2010-07-16 주식회사 동아지질 석션 드레인 공법에 사용되는 배수재 연결구
JP6958860B2 (ja) 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6262069B1 (en) * 1997-08-29 2001-07-17 Protherics Molecular Design Limited 1-amino-7-isoquinoline derivatives as serine protease inhibitors
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
DE60022508T2 (de) * 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
FR2800615B1 (fr) * 1999-11-05 2002-05-03 Sod Conseils Rech Applic Produit comprenant au moins une substance inhibitrice des no synthases en association avec au moins une substance inhibitrice des phospholipases a2

Also Published As

Publication number Publication date
IL159548A0 (en) 2004-06-01
DE60213424D1 (de) 2006-09-07
HUP0500484A3 (en) 2005-09-28
HU228783B1 (en) 2013-05-28
HUP0500557A3 (en) 2006-02-28
IS2366B (is) 2008-06-15
DE60213424T2 (de) 2007-08-23
MXPA04000752A (es) 2004-04-20
FR2827772A1 (fr) 2003-01-31
PT1414447E (pt) 2006-12-29
HU229425B1 (en) 2013-12-30
CY1106212T1 (el) 2011-06-08
KR20040030843A (ko) 2004-04-09
EP1414447A1 (fr) 2004-05-06
CA2455635C (fr) 2011-05-31
NO20040280L (no) 2004-01-21
NO334797B1 (no) 2014-05-26
US20040248885A1 (en) 2004-12-09
PL206706B1 (pl) 2010-09-30
TWI309568B (en) 2009-05-11
BR0211423A (pt) 2004-08-17
WO2003009843A1 (fr) 2003-02-06
AU2002341008B8 (en) 2007-08-09
AU2002341008A1 (en) 2003-02-17
HK1069326A1 (en) 2005-05-20
US20080039451A1 (en) 2008-02-14
JP4491229B2 (ja) 2010-06-30
HU0500484D0 (en) 2005-07-28
AU2002341008B2 (en) 2007-03-08
PL368315A1 (en) 2005-03-21
CN1533276A (zh) 2004-09-29
IL159548A (en) 2009-11-18
CA2455635A1 (fr) 2003-02-06
ATE333876T1 (de) 2006-08-15
EP1414447B1 (fr) 2006-07-26
CN1533276B (zh) 2010-06-30
RU2297832C2 (ru) 2007-04-27
IS7100A (is) 2004-01-09
FR2827772B1 (fr) 2006-04-28
NZ530368A (en) 2005-04-29
JP2005500337A (ja) 2005-01-06
DK1414447T3 (da) 2006-11-27
US20070185174A1 (en) 2007-08-09
US7345066B2 (en) 2008-03-18
RU2004105653A (ru) 2005-04-10
ES2268099T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
HUP0500440A2 (hu) Acil-4-karboxi-fenil-karbamid-származékok, azokat tartalmazó gyógyszerkészítmények, eljárás ezek előállítására és ezek alkalmazása
CA2475432A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
HUP0401067A2 (hu) Defenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69827785D1 (de) 1,4-substituierte cyclische aminderivate
HUP0302825A2 (hu) Lipidben gazdag plakkok csökkentésére szolgáló szerek
HUP0400887A2 (hu) Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
ATE366249T1 (de) Zyklische amid-derivate
HUP0204474A2 (hu) 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1108025T1 (el) Παραγωγα n-[φαινυλο (πιπεριδινο-2-υλο)μεθυλο] βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO972666D0 (no) Anilinderivater med nitrogenmonoksyd-synteseinhiberende aktivitet
HUP0105039A2 (hu) Fungicid hatású propargil-éter-származékok, előállításuk és alkalmazásuk
HUP0402227A2 (hu) Fenil-szubsztituált triazolok és az AKL5 kináz szelektív inhibitoraiként történő felhasználásuk és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0302038A2 (hu) Biguanidszármazékok alkalmazása hegesedést elżsegítż gyógyszerek elżállítására
HUP0402290A2 (hu) A 4"-helyzetben amino-szulfonil-oxi-szubsztituenst tartalmazó avermektin B1-származékok
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
CA2208639A1 (en) Camptothecin derivatives and its manufacturing method
DK0625967T3 (da) N,N-substituerede imidocarbonimiddiamider deriveret af hydroxylaminer
HUP0500557A2 (hu) Tiazolszármazékok alkalmazása mitokondriumok védelmére szolgáló gyógyszer előállítására
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
DK1095029T3 (da) Piperazinderivater til hæmning af replikationen af humant immundefekt virus
HUP0500203A2 (hu) Acil-3-karboxi-fenil-karbamid-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
HUP0204217A2 (en) Novel a-500359 derivatives
HUP0402585A2 (hu) Új benzotiazin- benzotiadiazin-származékok, előállításuk, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: IPSEN PHARMA S.A.S., FR

Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.), FR

MM4A Lapse of definitive patent protection due to non-payment of fees